Methotrexate for psoriasis in the era of biological therapy

Clinical and Experimental Dermatology

Volumn 33, Issue 5, 2008, Pages 551-554

  Warren, R B ^a   Chalmers, R J G ^a   Griffiths, C E M ^a   Menter, A ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; PROCOLLAGEN; PRODRUG;

BIOLOGICAL THERAPY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOXICITY; DRUG TRANSFORMATION; DRUG UTILIZATION; GENETIC POLYMORPHISM; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; PHARMACODYNAMICS; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; BIOPSY; DERMATOLOGIC AGENTS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; METHOTREXATE; PSORIASIS;

EID: 49649126378     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02976.x     Document Type: Review

References (28)

1. Fairris GM, White JE, Leppard BJ et al. Methotrexate for intractable benign familial chronic pemphigus. Br J Dermatol 1986 115: 640.
2. Metzger AL, Bohan A, Goldberg LS et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974 81: 182 9.
3. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977 97: 213 6.
4. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951 221: 176 82.
5. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158: 558 66.
6. Kirby B, Lyon CC, Griffiths CE et al. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin Exp Dermatol 2000 25: 265 8.
7. Salim A, Tan E, Ilchyshyn A et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006 154: 1169 74.
8. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008 58: 73 81.
9. Roenigk HH Jr., Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38: 478 85.
10. MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol 2005 152: 405 8.
11. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 152: 444 50.
12. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994 130: 204 10.
13. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000 14: 382 8.
14. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002 4: 266 73.
15. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366: 1367 74.
16. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371: 1675 84.
17. Flytstrom I, Stenberg B, Svensson A et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008 158: 116 21.
18. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 349: 658 65.
19. Bannwarth B, Pehourcq F, Schaeverbeke T et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996 30: 194 210.
20. Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med 1994 370: 411 6.
21. Hroch M, Chladek J, Simkova M et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008 22: 19 24.
22. Dervieux T, Orentas LD, Marcelletti J et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003 49: 1632 41.
23. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157: 238 44.
24. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med Kinderheilkd 1959 12: 52 125.
25. Campalani E, Arenas M, Marinaki AM et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007 127: 1860 7.
26. Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008 128: 1925 29.
27. Warren RB, Smith R, Campalani E et al. Genetic variation across the methotrexate metabolic pathway and its influence upon treatment outcomes in patients with psoriasis. Br J Dermatol 2007, 157 (Suppl. 1 2 3 (Abstract).
28. Warren RB, Griffiths CEM. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol 2005 153: 869 73.